Pfizer yesterday asked the Food and Drug Administration to amend the emergency use authorization for its COVID-19 vaccine to allow all individuals age 18 and older to receive booster shots. In its request, Pfizer cited data from its ongoing phase 3 clinical trial that confirm the efficacy and safety of a third, 30-microgram dose of the vaccine.

Related News Articles

Headline
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Etiam ac tortor pulvinar massa vehicula laoreet a sit amet magna. Pellentesque quis molestie justo, at…
Headline
The Centers for Medicare & Medicaid Services today released updated interpretive guidance on its Omnibus COVID-19 Health Care Staff Vaccination…
Blog
To help hospitals and health system leaders stay up-to-date on all of the legal developments related to vaccine mandates, the AHA has developed a blog…
Headline
Leaders from the AHA and the American College of Obstetricians and Gynecologists, hospital leaders, clinicians and experts from the Centers for Disease Control…
Headline
A new AHA video is tackling prominent myths about COVID-19 and its vaccines, providing the public with the facts they need to make sound health decisions…
Headline
In addition to the seven new 2022 ICD-10 procedure codes announced in November, the Centers for Medicare & Medicaid Services on April 1 will implement…